Esperion CFO granted options and shares

Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported equity awards.

Rhea-AI Filing Summary

Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported equity awards. He received a grant of 221,270 stock options to buy Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036. He was also granted 247,430 shares of Common Stock, bringing his direct holdings to 720,026 shares. The option award will vest over four years in equal quarterly installments, starting on June 15, 2026. Halladay’s reported holdings include 5,071 shares recently acquired through Esperion’s Employee Stock Purchase Plan.

Insider Trade Summary

Grant/Award: 468,700 shares

Grant/Award 2 txns

Insider Halladay Benjamin

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	221,270	$0.00	$0.00
Grant/Award	Common Stock	247,430	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 221,270 contracts (Direct); Common Stock — 720,026 shares (Direct)

Footnotes (2)

1. F1. Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.
2. F2. Includes 5,071 shares recently acquired in Esperion's Employee Stock Purchase Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Esperion Therapeutics (ESPR) CFO Benjamin Halladay report on this Form 4?

Esperion’s CFO Benjamin Halladay reported receiving equity compensation awards, including stock options and Common Stock. These awards increase his direct ownership in Esperion and are structured as grants rather than open-market purchases or sales.

How many stock options did ESPR CFO Benjamin Halladay receive?

Benjamin Halladay received 221,270 stock options, each giving the right to buy one share of Esperion Common Stock. The options have an exercise price of $2.44 per share and an expiration date of March 13, 2036, forming a long-term incentive grant.

What Common Stock grant did ESPR CFO Benjamin Halladay receive and what are his total shares?

He was granted 247,430 shares of Esperion Common Stock as part of his equity compensation. Following this award, Halladay directly owns 720,026 shares, which includes a portion acquired through Esperion’s Employee Stock Purchase Plan.

What is the vesting schedule for Benjamin Halladay’s Esperion stock option grant?

The stock option award will vest over four years in equal quarterly installments. The first vesting date is June 15, 2026, meaning portions of the 221,270 options become exercisable every quarter across the four-year period.

What is the exercise price and expiration date of the ESPR CFO’s options?

The options have an exercise price of $2.44 per share, allowing purchase of Esperion Common Stock at that price. They expire on March 13, 2036, providing a long window during which Halladay can choose to exercise vested options.

Are any of Benjamin Halladay’s reported ESPR shares from an Employee Stock Purchase Plan?

Yes. The reported holdings include 5,071 shares recently acquired through Esperion’s Employee Stock Purchase Plan. These ESPP shares are part of his total 720,026 directly owned Common Stock shares disclosed after the new equity grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Halladay Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		247,430(1)	A	$0	720,026(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.44	03/13/2026		A		221,270		(1)	03/13/2036	Common Stock	221,270	$0	221,270	D

Explanation of Responses:

1. Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.

2. Includes 5,071 shares recently acquired in Esperion's Employee Stock Purchase Plan.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.